

## Corium International (CORI : US\$5.74)

### Corium International tumbles 28% in 2014

Corium International Inc, NASDAQ's 41st largest healthcare-products company by market cap, has now tumbled US\$2.26 (or 28.2%) year to date in 2014 to close at US\$5.74. The volume YTD has been 0.6 times average trading of 22,151 shares. Compared with the NASDAQ-100 Index which rose 295.6 points (or 7.6%) in the quarter, this represented a relative price change of -23.5%. In 2014 the market cap has declined US\$37.6 million.

### Introduction

**We are currently bearish on this stock, both in the short-term based on technical indicators, as well as in the long-term based on fundamental metrics**

**What makes us most bearish on the stock is the following:**

- Its Moving Average Convergence Divergence indicators are falling, with its 12-day EMA lower than its 26-day EMA.
- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 2.3. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.
- The price to 200-day MAP ratio is 0.72, a bearish indicator.
- In the last three months the number of falls outnumbered rises 25:23 or 1.09:1.

**However, there are some reasons why some in the market are more bullish on the stock:**

- Amongst stocks that are shorted, it was in the bottom quartile as a percentage of stock shorted, suggesting that there are fewer confident bears of the stock.

### Stock Summary

<b>Sector</b>	Healthcare-Products
<b>Market Cap</b>	US\$103.3 million
<b>Shares Outstanding</b>	18,000,419
<b>ISIN</b>	US21887L1070
<b>Relative Strength (3 mo)</b>	19

### MCap: A Historical Perspective

	Share Price (USD)	Market Cap (US\$)
Last	5.7	103.3 million

## Analysis

### Bullish Signals

- The price is at a discount of 3.0% to the 1-month volume weighted average price of US\$5.92, which may appeal as a value proposition.
- In the last 5 trading sessions there has been a net rise of 1.95%; the stock has advanced eight times and the biggest one day rise was 8.9% on Oct 21.
- The Price/MAP of 0.72 for CORI is higher than the Price/MAP for the NASDAQ-100 Index of 0.4.
- In the NASDAQ Short Selling market of 2425 stocks, short selling as a % of issued shares ranked 1939th and within the bottom quartile of stocks. This means it was lower than market average of 0.55%, a bullish indicator.

### Undervaluation:


- The company is cash rich with Cash to Market Capitalisation at 13.1%.

### Other Bullish Signals:

#### Bullish Indicators and Rank in Market:

Description	Value	Rank In Market
Price Change %	5.9	In Top 4%
P/E * P/NTA	11.76	In Top Quartile

### Revenue Share Healthcare-Products



### Bearish Signals

- Falls to Rises: In the last three months the number of falls outnumbered rises 25:23 or 1.09:1.
- In the NASDAQ market of 2,401 stocks traded today, the stock has a 6-month relative strength of 17 indicating it is trailing 83.0% of the market.

- The Moving Average Convergence Divergence (MACD) indicator of 12-day Exponential Moving Average (EMA) of 5.55 minus the 26-day EMA of 5.71 is negative suggesting a bearish signal.
- The price to 200-day MAP ratio is 0.72, a bearish indicator. In the past 200 days this ratio has been under 0.72 just six times suggesting a support level. The 200-day MAP has decreased to US\$7.99. A decrease is another bearish indicator.
- The current short volume is 1.2 times its own historical average of 0.02%.

### Overvaluation:

- The Q Ratio, defined by James Tobin as MCap divided by Total Assets, is 2.3. Compared with the rest of the market the stock is overvalued and ranks in the bottom quartile of stocks by value of Q Ratio.

### Other Bearish Signals:

- Total Liabilities/ EBITDA of 59 is more than or equal to 5, this compares unfavourably with the Joseph Piotroski benchmark of 5.
- Net Profit margin has been negative in recent years.

### Annual Trend:

[Year ended, all figures in %]:

Year	Net Profit Margin	EBIT Margin	EBITDA Margin
Sep 13	-27.6	2.4	3.5
Sep 12	-12.7	-0.5	0.7

### % Growth Y.O.Y, Revenue & Net Profit



The stock has a score of merely 2 out of 9 set by Joseph Piotroski [pass mark >=5 ]:

Total shares on issue unchanged; improvement in gross margin [from 19.3% to 27%].

## Analysis (continued)

### Bearish Indicators and Rank in Market:

Description	Value	Rank In Market
Relative Strength (6M)	17	In Bottom Quartile
Turnover in Quarter	US\$5.4 million	In Bottom Quartile
Volatility %	5.7	In Bottom Quartile
Return on Capital Employed [ROCE] %	4.2	In Bottom Quartile
Price/MAP200	0.72	In Bottom Quartile
EBITDA Margin %	3.5	In Bottom Quartile
Price/MAP50	0.49	In Bottom 4%

## Note


### Neutral Indicators and Rank in Market:

Description	Value	Rank In Market
MCap	US\$103.3 million	In 3rd Quartile

## Insider Trades




## Turnover Rate & Turnover Period



## Trailing 3 months

Turnover	US\$5.4 million
Volume	899,248
Volume Index (1 is avg)	0.6


## YTD Comparison Stock Sector Index




## Price Volume Trend: Trailing Quarter



## Weekly Price Volume Dynamics (Last 12 Weeks)



## Stock v Index (Trailing Year)



## Price/Moving Average Price [P/MAP]



## Reported Buying Selling by Insiders

Insider	Date	Transaction Type	No. of Shares	Price, US\$	Value, US\$
Staple Peter D	Aug 27, 2014	Bought	300	6.2	1,860
Staple Peter D	Aug 25, 2014	Bought	1,278	6.04	7,719

## Company Overview

### Regulatory Announcements

---

To view Recent Company Headlines, [click here](#)

September 18: Corium Announces Appointment of Paul Goddard, Ph.D. to Board of Directors

August 27: Corium International insider buys; shares at a one-month high

August 27: Corium International insider buys; shares at a one-month high

August 05: Corium to Report Third Quarter Fiscal Year 2014 Financial Results on Tuesday, August 12, 2014

May 30: Corium International insider buys; shares at a ten-day high

May 28: Corium to Present at Jefferies 2014 Global Healthcare Conference

May 13: Corium Reports Second Fiscal Quarter 2014 Financial Results

### Issued Capital

---

Based on 18,000,419 issued equity shares the market capitalisation is US\$103.3 million. It is NASDAQ's 21st largest Healthcare-Products company by assets.

## Board and Management

### **Peter D. Staple** **CEO & President**

Mr. Staple has more than 25 years of experience in the biotech and pharmaceutical industries. He has previously served as Chief Executive Officer and a Director of BioSeek, Inc., a pioneer in applying predictive human biology to drug discovery, and as a member of the senior executive team at ALZA Corporation, the leader in applying drug delivery technologies to develop new therapeutics. At ALZA, as Executive Vice President, Chief Administrative Officer and General Counsel, he played a central role in partnering transactions, financings and acquisitions, as well as ALZA's merger with Johnson & Johnson.



# Financial Results (Quarterly)

31 March, 2014

## INCOME STATEMENT

Currency in Thousand of USD	2014-03-31	2013-03-31	Change %
<b>Revenues:</b>			
Product revenues	7,240	10,218	Down 29.1
Contract research and development revenues	3,173	2,174	Up 46.0
Other revenues	304	144	Up 111.1
Total revenues	10,717	12,536	Down 14.5
<b>Costs and operating expenses:</b>			
Cost of product revenues	4,998	6,583	Down 24.1
Cost of contract research and development revenues	3,911	2,820	Up 38.7
Research and development expenses	1,267	1,520	Down 16.6
General and administrative expenses	1,236	1,606	Down 23.0
Amortization of intangible assets	131	133	Down 1.5
Gain on disposal and sale and leaseback of equipment	-32	-48	Reduced 33.3
Total costs and operating expenses	11,511	12,614	Down 8.7
Income (loss) from operations	-794	-78	Deterioration 917.9
Interest income	1	2	Down 50.0
Interest expense	1,780	1,923	Down 7.4
Change in fair value of preferred stock warrant liability	-231		
Change in fair value of subordinated note embedded derivative liability	6,338		
Income (loss) before income taxes	3,534	-1,999	Recovery
<b>Income tax benefit (expense)</b>			
Net Income (loss) and comprehensive income (loss)	3,534	-1,999	Recovery
Net Income (loss) per share attributable to common stockholders, 50.0c basic		-90.0c	Recovery
Net Income (loss) per share attributable to common stockholders, 33.0c diluted		-90.0c	Recovery
Weighted average shares used in computing net income (loss) per share attributable to common stockholders, basic	2,232,300	2,225,742	Up 0.3
Weighted average shares used in computing net income (loss) per share attributable to common stockholders, diluted	5,930,309	2,225,742	Up 166.4

## BALANCE SHEET

Currency in Thousand of USD	2014-03-31	2013-09-30	Change %
<b>ASSETS</b>			



# Financial Results (Quarterly) (continued)

31 March, 2014

Current assets:			
Cash and cash equivalents	5,333	13,581	Down 60.7
Accounts receivable, net	4,257	3,129	Up 36.0
Unbilled accounts receivable	2,343	1,495	Up 56.7
Inventories, net	3,040	4,508	Down 32.6
Prepaid expenses and other current assets	2,415	1,038	Up 132.7
Total current assets	17,388	23,751	Down 26.8
Property and equipment, net	12,104	12,622	Down 4.1
Debt financing costs, net	731	902	Down 19.0
Intangible assets, net	6,694	6,647	Up 0.7
Notes receivable - related parties		100	
TOTAL ASSETS	36,917	44,022	Down 16.1
LIABILITIES, CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' DEFICIT			
Current liabilities:			
Accounts payable	1,791	2,748	Down 34.8
Accrued expenses and other current liabilities	4,072	3,374	Up 20.7
Bank lines of credit	2,658	3,873	Down 31.4
Long-term debt, current portion	38	457	Down 91.7
Capital lease obligations, current portion	895	1,029	Down 13.0
Preferred stock warrant liability	834	560	Up 48.9
Recall liability, current portion	774	1,004	Down 22.9
Deferred contract revenues, current portion	2,324	2,112	Up 10.0
Total current liabilities	13,386	15,157	Down 11.7
Long-term interest payable	12,413	11,590	Up 7.1
Long-term debt, net of current portion	37,584	36,956	Up 1.7
Convertible notes	9,475	9,399	Up 0.8
Subordinated note	16,199	13,000	Up 24.6
Subordinated note embedded derivative liability		7,367	
Capital lease obligations, net of current portion	1,274	1,652	Down 22.9
Recall liability, net of current portion	3,431	3,828	Down 10.4
Deferred contract revenues, net of current portion	3,562	3,688	Down 3.4
Total liabilities	97,324	102,637	Down 5.2
Convertible preferred stock	57,261	57,261	Steady
Redeemable common stock	3,224	3,224	Steady
Stockholders' deficit:			
Common stock	2	2	Steady
Additional paid-in capital	-29,907	-26,679	Deterioration 12.1
Accumulated deficit	-90,987	-92,423	Reduced 1.6
Total stockholders' deficit	-120,892	-119,100	Deterioration 1.5
TOTAL LIABILITIES, CONVERTIBLE PREFERRED STOCK, REDEEMABLE COMMON STOCK AND STOCKHOLDERS' DEFICIT	36,917	44,022	Down 16.1

# Financial Results (Quarterly) (continued)

31 March, 2014

## PERFORMANCE RATIOS

	2014-03-31	2013-03-31	Change %
Return on Equity(%)	-1.19	2.88	Deterioration
Return on Assets(%)	3.89	-7.8	Recovery

## PER SHARE FIGURES

	2014-03-31	2013-03-31	Change %
EPS	2.0c	-155.0c	Recovery

BuySellSignals Financial Research provides equity research on over 48,000 companies listed in more than 90 countries and 120 markets across the world. BuySellSignals believes that every stock has a story to tell and that this story changes every day. To capture this story, BuySellSignals offers the latest pertinent and comprehensive information so that investors can make well-informed investment decisions.

BuySellSignals publishes equity research reports on each stock, sector and index daily to capture the latest market movements and sentiments. BuySellSignals eschews "hot tip" or headline investing in favour of high-quality, ultra-current, targeted technical and fundamental information including specific bullish and bearish signals for each stock. Insights that will guide you to the investments that are hard to find in today's hyperactive mainstream markets.

For further details on definitions and quotations from investing legends, [Click here](#)

---

Disclaimer: While this document is based on information sources which are considered reliable, it has been prepared without consideration of your specific investment objectives, financial situation or needs, so you should carry out your own analysis or seek professional investment advice before an investment decision is made. The document contains unbiased, independent equities data from BuySellSignals (AFS Licence 222756) and News Bites Pty Ltd, who provide round the clock data on every Australian stock and sector. Neither BuySellSignals nor News Bites are brokers, and neither have an executing, corporate advisory or investment banking function. BuySellSignals and News Bites Pty Ltd, its directors, employees and consultants do not represent, warrant or guarantee, expressly or impliedly, that the information contained in this document is complete or accurate. The data is sourced from annual reports and company releases and may not be fully up to date. It should be used as a guide only.

---